ProCE Banner Activity


Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes With Novel Approaches to Targeted Therapy


Watch this webcast from a live presentation by John Allan, MD, for an expert perspective on recent developments in the therapeutic landscape for relapsed/refractory DLBCL.

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™ 

US Physicians: maximum of 1.00 Medical Knowledge MOC point

Released: August 21, 2023

Expiration: August 20, 2024



John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Provided by

Jointly provided by USF Health and Rockpointe

ProCE Banner
ProCE Banner


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

While the introduction of CD20-targeted chemoimmunotherapy drastically improved outcomes for diffuse large B-cell lymphoma (DLBCL), many patients relapse and the outlook for relapsed/refractory disease is poor. In recent years, several novel targeted therapies have emerged for the treatment of patients who have progressed on frontline chemoimmunotherapy. These therapies, including monoclonal antibodies, bi-specific antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors have provided much needed hope for patients with relapsed disease, resulting in significant improvements in long-term outcomes. Despite this, many patients do not receive these treatments due to a lack of familiarity among hematologists and oncologists with newly approved and emerging regimens and how uncertainty regarding which agents to use in each setting. These clinicians require guidance on how best to integrate these agents into clinical practice. Additionally, several novel treatments are currently in development for relapsed/refractory DLBCL. Hematologists and oncologists need to be aware of these emerging treatments so they can be prepared to integrate these agents into their practice. This educational initiative will provide hematologists and oncologists with needed education surrounding recently approved treatments for DLBCL and treatment options on the horizon. This will include a discussion of the different classes of therapy approved and in development for relapsed/refractory DLBCL, supporting clinical trial data, and expert guidance on how best to incorporate new therapies into the care of patients with relapsed/refractory DLBCL.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with relapsed or refractory diffuse large B-cell lymphomas.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Outline the most recent treatment guidelines for relapsed/refractory DLBCL, including the role of novel targeted therapies in the treatment paradigm

  • Evaluate novel targeted therapies currently in development for treatment of relapsed/refractory DLBCL.

  • Develop personalized treatment plans for patients with relapsed/refractory DLBCL based on clinical trial data and guideline and expert recommendations


Relevant Financial Relationships Disclosure

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John Allan, MD: consultant: AbbVie, Adaptive Biotech, ADC Therapeutics, AstraZeneca, BeiGene, Epizyme, Genentech, Janssen, Lilly, Pharmacyclics, TG Therapeutics; grants/research support: BeiGene, CelGene, Genentech, Janssen, TG Therapeutics; speakers bureau: AbbVie, BeiGene, Janssen, Pharmacyclics.

Content Reviewer

Subrena Powell, AGACNP-BC, has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and Rockpointe staff have no relevant financial interests/relationships or affiliations in relation to this activity.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 21, 2023, through August 20, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

Learners must successfully complete the post-test and evaluation to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about accreditation of this activity, please email:



Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is USF Health’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Participant’s MOC Points. No MOC certificates will be provided. Participants with questions regarding their Points, should contact USF Health at